AMERICAN JOURNAL OF HEMATOLOGY
Scope & Guideline
Pioneering Insights for Tomorrow's Hematology
Introduction
Aims and Scopes
- Hematological Malignancies:
The journal extensively covers research on leukemia, lymphoma, and myeloma, focusing on novel therapies, clinical trials, and molecular genetics that influence treatment and prognosis. - Transfusion Medicine:
Research related to transfusion practices, blood safety, and the management of transfusion-related complications is a key area, reflecting the journal's commitment to improving patient care in transfusion settings. - Sickle Cell Disease and Thalassemia:
Papers often explore the pathophysiology, management strategies, and innovative therapies for sickle cell disease and thalassemia, aiming to improve health outcomes for affected individuals. - Coagulation Disorders:
The journal includes research on various coagulation disorders, including hemophilia and thrombosis, focusing on new treatment modalities and strategies for management. - Stem Cell Transplantation:
There is a significant emphasis on studies related to hematopoietic stem cell transplantation, including donor selection, conditioning regimens, and post-transplant outcomes. - Clinical Trials and Therapeutics:
The journal publishes findings from clinical trials of new drugs, treatment regimens, and innovative therapies, contributing to the evidence base for clinical practice.
Trending and Emerging
- Immunotherapy and CAR-T Cell Therapy:
There is a growing emphasis on the development and application of immunotherapies, particularly CAR-T cell therapies, for hematological malignancies, showcasing innovative treatment options. - Targeted Therapy and Precision Medicine:
Research focusing on targeted therapies based on genetic and molecular profiling of hematological disorders is on the rise, reflecting a shift towards personalized treatment approaches. - Biomarkers and Minimal Residual Disease Monitoring:
Emerging studies are increasingly focusing on the identification and utilization of biomarkers for disease monitoring and prognosis, particularly in acute myeloid leukemia and other malignancies. - Health Disparities and Patient-Centered Care:
The journal is increasingly addressing health disparities within hematology, emphasizing the importance of equitable care and patient-reported outcomes in treatment strategies. - Long-term Effects of COVID-19 on Hematology Patients:
Research exploring the implications of COVID-19 on patients with existing hematological conditions, including vaccine responses and management challenges, has gained prominence. - Artificial Intelligence and Machine Learning in Hematology:
There is a notable trend towards integrating artificial intelligence and machine learning into hematology research, particularly in diagnostics and treatment personalization.
Declining or Waning
- Traditional Chemotherapy Approaches:
There is a noticeable decrease in studies focusing solely on traditional chemotherapy regimens as the field moves towards targeted therapies and immunotherapies, which are now the focus of many clinical trials. - Basic Science Research:
The journal has shifted towards more clinically relevant studies, with a waning interest in purely basic science research that does not directly translate to clinical applications. - Epidemiological Studies:
Although still important, there appears to be a reduction in the volume of studies that solely focus on the epidemiology of hematological disorders, as the emphasis shifts towards treatment outcomes and therapeutic innovations. - Longitudinal Studies in Hematology:
Fewer longitudinal studies are being published, as funding and interest may be shifting towards more immediate, impactful clinical trials and translational research.
Similar Journals
HemaSphere
Fostering global collaboration in hematologic studies.HemaSphere, published by WILEY, stands at the forefront of hematology research, offering a vital platform for the dissemination of cutting-edge findings in the field. Since its inception in 2017 and official transition to Open Access in 2018, the journal has positioned itself as a leading conduit for high-impact research, maintaining a prestigious Q1 quartile ranking in the Hematology category as of 2023. Addressed in the United States at 111 River St, Hoboken, NJ, HemaSphere aims to foster a global dialogue among researchers, clinicians, and students by providing unrestricted access to high-quality content that encompasses clinical and experimental advancements. With an array of engaging articles, reviews, and commentaries, HemaSphere contributes significantly to the advancement of hematology, ensuring that critical knowledge is readily accessible to enhance patient care and innovative research. To explore the latest developments and breakthroughs in this dynamic field, we invite scholars, professionals, and students to engage with HemaSphere and elevate their understanding of hematologic science.
Hematology-American Society of Hematology Education Program
Advancing Hematology through Expert EducationHematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.
Blood Transfusion
Empowering Research in Hematology and Immunology.Blood Transfusion is a leading journal in the fields of Hematology, Immunology, and Medicine, published by SIMTIPRO SRL in Italy. With its ISSN 1723-2007, the journal has established a significant presence in the academic community, as evidenced by its positioning within the Q2 category in Hematology and Medicine (miscellaneous) and Q3 in Immunology and Allergy for 2023. Notably, it ranks #38 out of 137 in the Hematology category, showcasing its impactful contributions to research and practice. Operating under a traditional publishing model, this journal provides valuable insights into advances in blood transfusion science, ultimately aimed at enhancing patient care and outcomes. Spanning from 2003 to 2024, the scope of Blood Transfusion covers a wide range of topics related to hematological and immunological research, making it an essential resource for researchers, healthcare professionals, and students engaged in these critical fields.
ANNALS OF HEMATOLOGY
Exploring breakthroughs in blood disorders and treatments.ANNALS OF HEMATOLOGY, published by Springer in Germany, stands as a premier platform for advancing knowledge in the field of hematology and medicine at large. With a significant impact factor and recognized rankings—Q2 in Hematology and Q1 in Medicine (miscellaneous) as of 2023—this journal is pivotal for researchers, clinicians, and students who are keen on exploring the latest developments in blood disorders, treatments, and innovative methodologies. Its broad scope encompasses original research, reviews, and discussions that aim to foster interdisciplinary dialogue, ensuring that the latest findings and theories are accessible to the scientific community. Although not an open-access journal, its rigorous peer-review process guarantees high-quality contributions, thereby solidifying its reputation as a vital resource in the hematological field. Founded in 1991, the ANNALS OF HEMATOLOGY continues to evolve, converging invaluable insights from both basic and clinical research until 2024. For those dedicated to improving patient outcomes and advancing hematological science, this journal remains an essential reference.
Journal of Blood Medicine
Empowering Research: Your Gateway to Innovations in HematologyThe Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.
Journal of Hematology
Advancing the Frontiers of Blood ScienceThe Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.
BLOOD REVIEWS
Connecting professionals through cutting-edge research.BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
Bridging research and practice in pediatric hematology and oncology.JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, published by Lippincott Williams & Wilkins, serves as a vital platform for the dissemination of cutting-edge research and insights in the fields of pediatric hematology and oncology. Since its inception in 1979, the journal has maintained a commitment to advancing knowledge through peer-reviewed articles that contribute to the understanding and treatment of blood disorders and cancers in children. With an impact factor reflective of its academic contributions, the journal is positioned in the Q3 quartile across key medical categories — Hematology, Oncology, and Pediatrics, Perinatology and Child Health — indicating its relevance and influence in the field. While it does not currently offer open access options, the journal remains a crucial resource for researchers, clinicians, and students dedicated to improving pediatric care and outcomes. Researchers are encouraged to contribute to this esteemed journal as it seeks to bridge the gap between clinical practice and research, fostering innovation and improved quality of life for young patients affected by hematologic and oncologic conditions.
BRITISH JOURNAL OF HAEMATOLOGY
Exploring Innovations in Blood Health and DiseaseBritish Journal of Haematology, published by Wiley, is a leading journal in the field of hematology, with an impressive impact factor reflecting its significance in the medical research community. Established in 1955, the journal has consistently contributed to advancing knowledge in hematology, currently holding a prestigious Q1 ranking in the Scopus category of Hematology, placing it in the top 18% of the field. The journal encompasses a broad range of topics including clinical and laboratory aspects of blood disorders and hematological malignancies, making it an essential resource for hematologists, researchers, and healthcare professionals. With its commitment to publishing top-tier research and clinical studies, the British Journal of Haematology plays a critical role in shaping treatment approaches and improving patient outcomes worldwide. Please note that this journal does not offer Open Access options, ensuring that published content is rigorously curated for quality and relevance.
EUROPEAN JOURNAL OF HAEMATOLOGY
Elevating Knowledge in Hematology Since 1986EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.